High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

Abstract

HD IL-2 can induce complete tumor regression in a small number of patients, and many patients have experienced extended disease-free intervals. Given its relative safety, HD IL-2 should still be considered a first-line therapy in patients with metastatic RCC who have an overall good performance status.